These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Current treatment of autoimmune blistering diseases. Kasperkiewicz M; Schmidt E Curr Drug Discov Technol; 2009 Dec; 6(4):270-80. PubMed ID: 20025595 [TBL] [Abstract][Full Text] [Related]
7. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication. Kolesnik M; Becker E; Reinhold D; Ambach A; Heim MU; Gollnick H; Bonnekoh B J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):771-80. PubMed ID: 23651052 [TBL] [Abstract][Full Text] [Related]
8. Autoimmune subepidermal blistering diseases in Uganda: correlation of autoantibody class with age of patients. Mulyowa GK; Jaeger G; Kabakyenga J; Bröcker EB; Zillikens D; Schmidt E Int J Dermatol; 2006 Sep; 45(9):1047-52. PubMed ID: 16961507 [TBL] [Abstract][Full Text] [Related]
9. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases. Daoud YJ; Amin KG Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922 [TBL] [Abstract][Full Text] [Related]
10. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. Segura S; Iranzo P; Martínez-de Pablo I; Mascaró JM; Alsina M; Herrero J; Herrero C J Am Acad Dermatol; 2007 Jun; 56(6):960-7. PubMed ID: 17368865 [TBL] [Abstract][Full Text] [Related]
12. [Successful use of combined corticosteroids and rituximab in the treatment of recalcitrant epidermolysis bullosa acquisita]. Cavailhes A; Balme B; Gilbert D; Skowron F Ann Dermatol Venereol; 2009 Nov; 136(11):795-9. PubMed ID: 19917432 [TBL] [Abstract][Full Text] [Related]
14. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. Shimanovich I; Mihai S; Oostingh GJ; Ilenchuk TT; Bröcker EB; Opdenakker G; Zillikens D; Sitaru C J Pathol; 2004 Dec; 204(5):519-27. PubMed ID: 15538734 [TBL] [Abstract][Full Text] [Related]
15. [Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases]. Kasperkiewicz M; Zillikens D Hautarzt; 2007 Feb; 58(2):115-6, 118-21. PubMed ID: 17237928 [TBL] [Abstract][Full Text] [Related]
16. Rituximab for patients with refractory mucous membrane pemphigoid. Le Roux-Villet C; Prost-Squarcioni C; Alexandre M; Caux F; Pascal F; Doan S; Brette MD; Soued I; Gabison É; Aucouturier F; Letestu R; Laroche L; Bachelez H Arch Dermatol; 2011 Jul; 147(7):843-9. PubMed ID: 21422323 [TBL] [Abstract][Full Text] [Related]
17. A case of epidermolysis bullosa acquisita with clinical features of Brunsting-Perry pemphigoid showing an excellent response to colchicine. Tanaka N; Dainichi T; Ohyama B; Yasumoto S; Oono T; Iwatsuki K; Elfert S; Fritsch A; Bruckner-Tuderman L; Hashimoto T J Am Acad Dermatol; 2009 Oct; 61(4):715-9. PubMed ID: 19679376 [TBL] [Abstract][Full Text] [Related]
18. Rituximab and its use in autoimmune bullous disorders. Daniel BS; Murrell DF; Joly P Dermatol Clin; 2011 Oct; 29(4):571-5. PubMed ID: 21925000 [TBL] [Abstract][Full Text] [Related]
19. Rituximab in dermatological diseases. Troiano M; Lotti T G Ital Dermatol Venereol; 2009 Aug; 144(4):495-9. PubMed ID: 19755955 [TBL] [Abstract][Full Text] [Related]